Adaptive cardiac remodeling by beta-catenin downregulation

摘要

The present invention relates to the use of an agent for downregulating or inhibiting β-catenin dependent signaling for the treatment of cardiovascular diseases or disorders,. as the specific inhibition of β-catenin dependent signaling by downregulating or inhibiting the expression or activity of β-catenin results in adaptive cardiac hypertrophy that is protective for example after angiotensin-II-induced stress.